Pharmaceuticals Native Starch Market Size Projected To Increase From $6.63 Billion To $9.22 Billion During The Forecast Period
Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Pharmaceuticals Native Starch Market Size And Revenue Forecast Through 2030
The market for native starch in pharmaceuticals has experienced significant expansion in recent years, with its value climbing from $6.11 billion in 2025 to $6.64 billion in 2026—a compound annual growth rate (CAGR) of 8.6%. Several factors have driven this growth in the historical period: the ready availability of natural starch sources, the broadening scope of generic pharmaceuticals, the prevalent utilization of tablets and capsules, cost considerations in drug formulation, and the regulatory endorsement of native starch.
The pharmaceuticals native starch market is projected to experience robust expansion over the coming years, reaching a valuation of $9.23 billion by 2030, driven by a compound annual growth rate (CAGR) of 8.6%. This anticipated growth during the forecast period is fueled by several key factors, including the rise of clean-label drug formulations, heightened sustainability demands, the broadening of pharmaceutical production in emerging economies, a growing preference for biodegradable excipients, and ongoing improvements in starch processing technologies. Among the prominent trends shaping this period are the escalating demand for natural and clean-label excipients, their increased application in solid oral dosage forms, wider adoption as binders and disintegrants, the expansion of plant-based pharmaceutical ingredients, and a stronger emphasis on cost-effective excipient solutions.
Download A Free Sample Report For Comprehensive Market Insights:
Pharmaceuticals Native Starch Market Industry Drivers: What Is Driving Revenue Growth?
The rising incidence of chronic illnesses is anticipated to drive forward the expansion of the pharmaceuticals native starch market. Chronic diseases are long-term medical conditions that develop gradually and endure for at least a year. This increase is largely due to the growing elderly population, as older individuals face a higher risk of conditions such as diabetes, cardiovascular ailments, arthritis, and cancer, all of which become more common with advancing age. Native starch in pharmaceuticals benefits chronic disease management by improving drug formulation stability, enhancing bioavailability, facilitating controlled drug release, promoting patient adherence, and thereby boosting both the effectiveness and sustained treatment of chronic health issues. For example, in April 2025, data from the Centers for Disease Control and Prevention, a U.S. federal public health organization, indicated that 76.4% of American adults, around 194 million people, reported having at least one chronic condition in 2023, with prevalence rates of 59.5% among young adults, 78.4% among middle-aged adults, and 93.0% among older adults. Consequently, the growing prevalence of chronic diseases is fueling the rise of the pharmaceuticals native starch market.
The growth of the pharmaceuticals native starch market is set to be driven by the expansion of generic drug manufacturing. This process involves producing off-patent medications that are bioequivalent to their branded counterparts. The rise in generic drug manufacturing stems from enhanced regulatory support that accelerates approvals and enables more companies to develop affordable substitutes for branded drugs. This expansion supports pharmaceuticals native starch by boosting demand for dependable, economical excipients that improve tablet formulation, stability, and drug delivery efficiency across a wide array of high-volume generic medications. In November 2024, the U.S.-based Food and Drug Administration (FDA) reported that 782 Abbreviated New Drug Applications (ANDAs) were approved in FY 2023, marking an increase from 722 in FY 2022. Thus, the growth of generic drug manufacturing is propelling the pharmaceuticals native starch market forward.
Pharmaceuticals Native Starch Market Segment Landscape: Which Areas Lead Market Development?
The pharmaceuticals native starch market covered in this report is segmented –
1) By Type: Potato Starch, Corn Starch, Other Types
2) By Formulation Type: Oral Solid Dosage Forms, Liquid Dosage Forms, Topical Formulations, Injectable Drugs, Controlled Release Formulations
3) By Functionality: Texturizing Agent, Moisture Retention Agent, Bulking Agent, Emulsifying Agent, Film-Forming Agent
4) By Application: Binders And Coating Agents, Disintegrants, Fillers And Extenders, Stabilizers, Thickening Agents
5) By End-User: Pharmaceutical Manufacturers, Contract Research Organizations (CROs), Contract Manufacturing Organizations (CMOs), Research And Development Labs, Academic Institutions, Other End-users
Subsegments:
1) By Potato Starch: Native Potato Starch (Pharmaceutical Grade), Low Moisture Native Potato Starch, Fine Particle Size Native Potato Starch, High Purity Native Potato Starch
2) By Corn Starch: Native Corn Starch (Pharmaceutical Grade), Low Moisture Native Corn Starch, Fine Particle Size Native Corn Starch, High Purity Native Corn Starch
3) By Other Types: Rice Starch, Wheat Starch, Tapioca Starch
Pharmaceuticals Native Starch Market Growth Trends: What Is Influencing The Future Outlook?
Key players in the pharmaceuticals native starch market are concentrating their efforts on creating innovative products—for example, textures derived from botanical sources—to improve medication composition and boost patient adherence to treatment. Such textures are defined by physical attributes obtained from plant ingredients, including thickness and gel strength, and they assist pharmaceutical applications of native starch by improving tablet binding, disintegration, and mouthfeel, thereby facilitating better natural drug formulations. As an example, in February 2024, Ingredion Incorporated, a U.S.-based food firm, introduced Novation Indulge 2940 starch, a clean-label texturizing agent designed to enhance texture and stability in dairy and alternative dairy items. This innovative pharmaceutical native starch provides functional characteristics that boost the performance of drug formulations, drug absorption, and sustained release, while simultaneously facilitating the creation of clean-label, sustainable products. NOVATION Indulge 2940 starch is a multipurpose component that enhances texture, stability, and consumer appeal in both dairy and alternative dairy products, by employing plant-derived, clean-label components.
Pharmaceuticals Native Starch Market Industry Leaders And Market Competition
Major companies operating in the pharmaceuticals native starch market are Cargill Incorporated, Archer Daniels Midland Company, Ingredion Incorporated, Roquette Frères SA, Emsland Group, Tereos SCA, AGRANA Beteiligungs-AG, Grain Processing Corporation, Universal Starch-Chem Allied Ltd., SPAC Starch Products (India) Private Limited, Sanstar Biopolymers Ltd., Gulshan Polyols Ltd., Tate & Lyle Public Limited Company, BENEO GmbH, Hungrana Kft., Bluecraft Agro Pvt. Ltd., Visco Starch, Manildra Group, Shandong Liujia Pharmaceutical Excipient Co. Ltd., Zhucheng Xingmao Corn Developing Co. Ltd.
Access The Complete Pharmaceuticals Native Starch Market Report:
Pharmaceuticals Native Starch Market Regional Outlook: Where Are The Largest Opportunities Located?
North America was the largest region in the pharmaceuticals native starch market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pharmaceuticals native starch market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
